Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
POINT Biopharma Global Inc. PNT
$9.45
+$0.44 (4.65%)
На 18:05, 12 мая 2023
+45.50%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
890907690.00000000
-
week52high
10.98
-
week52low
5.31
-
Revenue
-226352983437
-
P/E TTM
8
-
Beta
0.13342600
-
EPS
1.06000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 12:30
Описание компании
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-a targeting program being developed for use in multiple tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Guggenheim | Buy | 16 авг 2022 г. | |
| William Blair | Outperform | 06 июл 2022 г. | |
| Jefferies | Buy | Hold | 26 мая 2022 г. |
| Mizuho | Underperform | 17 дек 2021 г. | |
| Cowen & Co. | Outperform | 29 июл 2021 г. | |
| Truist Securities | Buy | 16 сент 2022 г. | |
| Berenberg | Buy | 14 сент 2022 г. | |
| JonesTrading | Buy | 07 сент 2022 г. | |
| Oppenheimer | Outperform | 11 окт 2022 г. | |
| Truist Securities | Buy | Buy | 15 ноя 2022 г. |
| Raymond James | Outperform | 14 дек 2022 г. | |
| SVB Leerink | Outperform | 30 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| MCCANN JOE A. | A | 3616313 | 2160 | 29 ноя 2022 г. |
| Malik Rajesh | A | 3700 | 3700 | 28 ноя 2022 г. |
| HOGUE GERALD L. | A | 3660 | 3660 | 25 ноя 2022 г. |
| Lubner David Charles | A | 3600 | 3600 | 23 ноя 2022 г. |
| MARGOLIN YAEL | A | 1710 | 1710 | 21 ноя 2022 г. |
| SILBER ALLAN C | A | 4268605 | 22397 | 18 ноя 2022 г. |
| GOODMAN JONATHAN R. | A | 41872 | 6000 | 18 ноя 2022 г. |
| SILBER ALLAN C | A | 4246208 | 27603 | 17 ноя 2022 г. |
| GOODMAN JONATHAN R. | A | 25614 | 25614 | 02 июн 2022 г. |
| HOGUE GERALD L. | A | 25614 | 25614 | 02 июн 2022 г. |
Новостная лента
POINT Biopharma to Participate in Upcoming Investor Conferences
GlobeNewsWire
02 февр 2023 г. в 08:30
INDIANAPOLIS, Feb. 02, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced management will participate in the following upcoming investor conferences:
Why Earnings Season Could Be Great for POINT Biopharma (PNT)
Zacks Investment Research
10 ноя 2022 г. в 08:17
POINT Biopharma (PNT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Why Point Biopharma Global Stock Got Crushed Today
The Motley Fool
14 сент 2022 г. в 18:44
The market didn't react well to news of the biotech's latest financing effort.
Why Point Biopharma Global Stock Is Getting Crushed Today
The Motley Fool
06 сент 2022 г. в 12:56
Short-sellers appear to be pouncing on an upcoming scientific presentation.
POINT Biopharma to Participate in Upcoming Investor Conferences
GlobeNewsWire
06 июл 2022 г. в 08:30
INDIANAPOLIS, July 06, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, will participate in the following upcoming investor conferences: